The threat of multiresistant microorganisms

  • C. M. J. E. Vandenbroucke-Grauls
Failure of Antimicrobial Treatment—The Microorganism Review


Enthusiasm about newly developed antimicrobial agents and disappointment because of the development of resistance have been alternating in the decades since the introduction of antibacterial chemotherapy around 1940. During the last few years several mechanisms of bacterial resistance have been elucidated, and new insights into the genetic basis of multiresistance have been gained. The clinical implications of multiresistance depend on timely recognition of the problem, i.e. knowledge of the epidemiology of multiresistant microorganisms and the availability of alternative drugs. A particular problem arises from the fact that infections with multiresistant microorganisms often occur in the most critically ill patients.


Internal Medicine Antimicrobial Agent Clinical Implication Genetic Basis Bacterial Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Burnet Sir M, White DO: Natural history of infectious diseases. Cambridge University Press, Cambridge, 1972, p. 176.Google Scholar
  2. 2.
    McGowan JE: Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Reviews of Infectious Diseases 1983, 5: 1033–1048.PubMedGoogle Scholar
  3. 3.
    Lowbury EJL, Ayliffe GAJ: Drug resistance in antimicrobial therapy. Charles Thomas Publisher, Spring-field, 1974, p. 3–8.Google Scholar
  4. 4.
    Shanson DC: Antibiotic-resistantStaphylococcus aureus. Journal of Hospital Infection 1981, 2: 11–36.CrossRefPubMedGoogle Scholar
  5. 5.
    Watanabe T: Infective heredity of multiple drug resistance in bacteria. Bacteriology Reviews 1963, 27: 87–115.Google Scholar
  6. 6.
    Mata LJ, Gangarosa EJ, Caceres A, Perera DR, Mejicanos ML: Epidemic shiga bacillus dysentery in Central America. I: Etiologic investigations in Guatemala, 1969. Journal of Infectious Diseases 1970, 122: 170–180.PubMedGoogle Scholar
  7. 7.
    World Health Organisation: Surveillance for the prevention and control of health hazards due to antibiotic-resistant enterobacteria: report of a WHO meeting. WHO Technical Report Series, 1978, No. 624.Google Scholar
  8. 8.
    Levine MM, DuPont HL, Formal SB, Gangarosa EJ: Epidemic shiga dysentery in Central America. Lancet 1970, ii: 607–608.Google Scholar
  9. 9.
    Thomas WJ, McReynolds JW, Mock CR: Ampicillin-resistantHaemophilus influenzae. Lancet 1974, i: 313.Google Scholar
  10. 10.
    Elwell LP, De Graaff J, Seibert D: Plasmid-linked ampicillin resistance inHaemophilus influenzae. Infection and Immunity 1975, 12: 404–410.PubMedGoogle Scholar
  11. 11.
    Manten A, van Klingeren B, Dessens-Kroon M: Chloramphenicol resistance inHaemophilus influenzae. Lancet 1976, i: 702.Google Scholar
  12. 12.
    Stuy JH: Plasmid transfer inHaemophilus influenzae. Journal of Bacteriology 1979, 139: 520–529.PubMedGoogle Scholar
  13. 13.
    Phillips I: Beta-lactamase-producing, penicillin-resistant gonococcus. Lancet 1976, ii: 656–657.Google Scholar
  14. 14.
    Brumfitt W, Hamilton-Miller J: Methicillin-resistantStaphylococcus aureus. New England Journal of Medicine 1989, 320: 1188–1196.PubMedGoogle Scholar
  15. 15.
    Skolnick A: New insights into how bacteria develop antibiotic resistance. Journal of the American Medical Association 1991, 265: 14–16.PubMedGoogle Scholar
  16. 16.
    Jacoby GA, Archer GL: New mechanisms of bacterial resistance to antimicrobial agents. New England Journal of Medicine 1991, 324: 601–612.PubMedGoogle Scholar
  17. 17.
    Murray BE: New aspects of antimicrobial resistance and the resulting therapeutic dilemmas. Journal of Infectious Diseases 1991, 163: 1185–1194.Google Scholar
  18. 18.
    Philippon A, Labia R, Jacoby G: Extended spectrum β-lactamases. Antimicrobial Agents and Chemotherapy 1989, 33: 1131–1136.PubMedGoogle Scholar
  19. 19.
    Nakamura S, Nakamura M, Kojima T, Yoshida H:gyrA andgyrB mutations in quinolone-resistant strains ofEscherichia coli. Antimicrobial Agents and Chemotherapy 1989, 33: 254–255.PubMedGoogle Scholar
  20. 20.
    Piddock LJV, Wise R: Mechanisms of resistance to quinolones and clinical perspectives. Journal of Antimicrobial Chemotherapy 1989, 23: 475–483.PubMedGoogle Scholar
  21. 21.
    Blumberg HM, Rimland D, Carrol DJ, Terry P, Wachsmuth IK: Rapid development of ciprofloxacin resistance in methicillin-susceptible and resistantStaphylococcus aureus. Journal of Infectious Diseases 1991, 163: 1279–1285.PubMedGoogle Scholar
  22. 22.
    Goldstein FW, Coutrot A, Sieffer A, Acar JF: Percentages and distribution of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrobial Agents and Chemotherapy 1990, 34: 899–900.PubMedGoogle Scholar
  23. 23.
    Murray BE: The life and times of the enterococcus. Clinical Microbiology Reviews 1990, 3: 46–65.PubMedGoogle Scholar
  24. 24.
    Leclerq R, Derlot E, Weber M, Duval J, Courvalin P: Transferable vancomycin and teicoplanin resistance inEnterococcus faecium. Antimicrobial Agents and Chemotherapy 1989, 33: 10–15.Google Scholar
  25. 25.
    Pitchenik AE, Burr J, Laufer M, Miller G, Cacciatore R, Bigler WJ, Witte JJ, Cleary T: Outbreaks of drug-resistant tuberculosis at an AIDS centre. Lancet 1990, 336: 440–441.CrossRefPubMedGoogle Scholar
  26. 26.
    Centers for Disease Control: Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons — Florida and New York, 1988–1991. Morbidity and Mortality Weekly Report 1991, 40: 585–591.Google Scholar
  27. 27.
    Kleckner N: Transposable elements in prokaryotes. Annual Review of Genetics 1981, 15: 341–404.CrossRefPubMedGoogle Scholar
  28. 28.
    Martinez E, de la Cruz F: Genetic elements involved in Tn21 site-specific integration, a novel mechanism for the dissemination of antibiotic resistance genes. EMBO Journal 1990, 9: 1275–1281.PubMedGoogle Scholar
  29. 29.
    Ward J: Antibiotic-resistantStreptococcus pneumoniae: clinical and epidemiologic aspects. Reviews of Infectious Diseases 1981, 3: 254–266.PubMedGoogle Scholar
  30. 30.
    Feldman C, Kallenbach JM, Miler SD, Thornburn JR, Koornhof HJ: Community-acquired pneumonia due to penicillin-resistant pneumococci. New England Journal of Medicine 1985, 313: 615–617.PubMedGoogle Scholar
  31. 31.
    Sanders WE, Sanders CC: Inducible β-lactamases: Clinical and epidemiologic implications for use of newer cephalosporins. Reviews of Infectious Diseases 1988, 10: 830–838.PubMedGoogle Scholar
  32. 32.
    Holmberg SD, Solomon SL, Blake PA: Health and economic impacts of antimicrobial resistance. Reviews of Infectious Diseases 1987, 9: 1065–1078.PubMedGoogle Scholar
  33. 33.
    O'Brien TF, Acar JF, Medeiros AA, Norton RA, Goldstein F, Kent RL: International comparison of prevalence of resistance to antibiotics. Journal of the American Medical Association 1978, 239: 1518–1523.CrossRefPubMedGoogle Scholar
  34. 34.
    McGowan JE, Hall EC, Parrott PL: Antimicrobial susceptibility in gram-negative bacteremia: are nosocomial isolates really more resistant? Antimicrobial Agents and Chemotherapy 1989, 33: 1855–1859.PubMedGoogle Scholar
  35. 35.
    Atkinson BA, Lorian V: Antimicrobial agent susceptibility patterns of bacteria in hospitals from 1971 to 1982. Journal of Clinical Microbiology 1984, 20: 791–796.PubMedGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1993

Authors and Affiliations

  • C. M. J. E. Vandenbroucke-Grauls
    • 1
  1. 1.Department of Clinical MicrobiologyUtrecht University HospitalUtrechtThe Netherlands

Personalised recommendations